The benefit of PARP inhibitors varied significantly based on the tumor's molecular profile, particularly its homologous recombination repair capability. While patients with deficiencies in this ...
The HER2CLIMB-05 study assessed the efficacy and safety of adding tucatinib to maintenance therapy with trastuzumab/pertuzumab in patients with HER2+ metastatic breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback